-
Symbol
-
LYEL on Nasdaq
-
Investment type
-
Equity / Common Stock, par value $0.0001 per share
-
Latest Disclosed Shares Owned
-
27,161,892 shares
-
Security Ownership %
-
9.2%
James B. Tananbaum ownership in Lyell Immunopharma, Inc. Common Stock, par value $0.0001 per share (LYEL)
15 May 2025 - James B. Tananbaum has filed an SCHEDULE 13G/A form with the Securities and Exchange Commission (SEC) disclosing ownership of 27,161,892 shares of Lyell Immunopharma, Inc. Common Stock, par value $0.0001 per share (LYEL).
This represents 9.2% ownership of the company.
In their previous filing dated 14 Feb 2025, Foresite Capital Fund IV, L.P. had reported owning 19,478,893 shares, indicating an increase of +39%.
.